MedTrace Logo

HHV-6-specific T-cell Reconstitution Among Children and Adolescents After Allogeneic Stem.

NCT06256341 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 53

Last updated 2024-02-13

No results posted yet for this study

Summary

Human herpesvirus 6 (HHV-6) causes only minor symptoms in healthy individuals but in immunosuppressed patients, e.g., patients after allogeneic stem cell transplantation (HSCT), HHV-6 reactivations can lead to diseases in different organ systems. HHV-6 reactivations have also been reported to be a cause for delayed engraftment, a trigger of graft-versus-host disease and a co-factor for other virus reactivations. T-lymphocytes play an important role in the control of virus reactivations. Little is known about the development of virus-specific T-cells after allogeneic HSCT.

Conditions

  • Allogeneic Stem Cell Transplantation

Interventions

OTHER

Cell cultivation, Antigen testing

day 10, peripheral blood mononuclear cells were re-stimulated with the virus antigen U54 for 6 hours and, thereafter, stained for surface markers (CD3, CD4, CD8, CD56) and intracytoplasmatic activation markers (IL-2, IFN-γ, TNF-α) for flow cytometric detection of virus-specific T-cells. T-cells with intracytoplasmic expression of activation markers after stimulation with the virus antigen are HHV-6-specific T-cells. This indicated HHV-6 specific cellular immunity. No more interventions in human except blood sampling, only basic research.

Sponsors & Collaborators

  • Medical University of Graz

    lead OTHER

Eligibility

Min Age
1 Year
Max Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2014-03-14
Primary Completion
2016-12-31
Completion
2023-11-01

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06256341 on ClinicalTrials.gov